Biodexa Pharmaceuticals annual shareholders’ equity
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Shareholders’ Equity Growth & History (BDRX)
Biodexa Pharmaceuticals's shareholders’ equity was £11.4M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £11.4M | £3.1M | +37.05% |
| 2024 | 2024-12-31 | £8.3M | £3.6M | +77.90% |
| 2023 | 2023-12-31 | £4.7M | £1.5M | +47.94% |
| 2022 | 2022-12-31 | £3.2M | −£7.3M | −69.75% |
| 2021 | 2021-12-31 | £10.5M | £3.7M | +55.58% |
| 2020 | 2020-12-31 | £6.7M | −£12.8M | −65.65% |
| 2019 | 2019-12-31 | £19.6M | £2.6M | +15.56% |
| 2018 | 2018-12-31 | £16.9M | −£17.8M | −51.19% |
| 2017 | 2017-12-31 | £34.7M | −£11.0M | −24.16% |
| 2016 | 2016-12-31 | £45.7M | −£1.2M | −2.48% |
| 2015 | 2015-12-31 | £46.9M | — | — |
Biodexa Pharmaceuticals quarterly shareholders’ equity
Q4.18
Q4.19
Q4.20
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | £11.4M | £3.1M | +37.05% |
| Q2 2025 | 2025-06-30 | £11.4M | £2.7M | +31.04% |
| Q4 2024 | 2024-12-31 | £8.3M | £3.6M | +77.90% |
| Q2 2024 | 2024-06-30 | £8.7M | £3.4M | +64.69% |
| Q4 2023 | 2023-12-31 | £4.7M | £1.5M | +47.94% |
| Q2 2023 | 2023-06-30 | £5.3M | −£2.2M | −29.26% |
| Q4 2022 | 2022-12-31 | £3.2M | −£7.3M | −69.75% |
| Q2 2022 | 2022-06-30 | £7.5M | — | — |
| Q4 2021 | 2021-12-31 | £10.5M | £3.7M | +55.58% |
| Q4 2020 | 2020-12-31 | £6.7M | −£12.8M | −65.65% |
| Q4 2019 | 2019-12-31 | £19.6M | £2.6M | +15.56% |
| Q4 2018 | 2018-12-31 | £16.9M | — | — |
Biodexa Pharmaceuticals shareholders’ equity trends
Over the last five fiscal years, Biodexa Pharmaceuticals's shareholders’ equity increased from £6.7M to £11.4M, a change of £4.7M. The latest reported quarter, Q4 2025, shows £11.4M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...